Trials / Terminated
TerminatedNCT01773785
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line Treatment for Patients With Advanced Biliary Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Spectrum Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to determine the effectiveness of SPI-1620 in combination with docetaxel in patients with advanced biliary cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPI-1620 | SPI-1620 11 μg/m2 will be given intravenously over 1 minute. |
| DRUG | Docetaxel | Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620. |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2013-01-23
- Last updated
- 2021-10-13
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01773785. Inclusion in this directory is not an endorsement.